unresectable head and neck squamous cell carcinoma
Conditions
Interventions
TACE combined with carrelizumab:TACE combined with carrelizumab
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed with head and neck squamous cell carcinoma by pathological, cytological and imaging examinations; 2. Evaluated by hospital MDT, it was clear that it was unresectable; 3. Be at least = 18 years old; 4. Refusal of chemoradiotherapy or failure of chemoradiotherapy; 5. Liver, kidney, heart and lung function are barrier-free, and there are no contraindications for interventional treatment; 6. Expected survival time is greater than 6 months; 7.PS score= 2 points; 8. Good treatment compliance, can complete treatment and follow-up.
Exclusion criteria
Exclusion criteria: 1. Allergic reactions to contrast media, chemotherapy drugs, camrelizumab, etc.; 2. Have severe and uncorrectable coagulation abnormalities; 3. Accompanied by severe infection or uncontrollable tumor-related complications; 4. After being informed, refuse to accept the above treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate(ORR);Disease control rate(DCR);Security;Overall survival(OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival(PFS); | — |
Countries
China
Contacts
Public ContactFei Gao
The Second Hospital of Dalian Medical University
Outcome results
None listed